Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-05-27
2008-05-27
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S015800
Reexamination Certificate
active
10528360
ABSTRACT:
Novel substituted type peptides of WT1 wherein the cysteine residue is substituted with a defined amino acid residue, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided.Peptides which comprise an amino acid sequence of the formula: X-Y-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 4) wherein X represents Ser, Ala, Abu, Arg, Lys, Orn, Cit, Leu, Phe, or Asn, and Y represents Tyr or Met, and which has an activity to induce CTLs, polynucleotides encoding said peptides, cancer vaccines which comprise those peptides or polynucleotides as an active ingredient, and the like are disclosed.
REFERENCES:
patent: 2004/0097703 (2004-05-01), Sugiyama
patent: 2004/0247609 (2004-12-01), Sugiyama
patent: 2005/0002951 (2005-01-01), Sugiyama et al.
patent: 2005/0266014 (2005-12-01), Sugiyama et al.
patent: 1 103 564 (2001-05-01), None
patent: 1 371 664 (2003-12-01), None
patent: 1 447 092 (2004-08-01), None
patent: 00 18795 (2000-04-01), None
patent: WO-02/079253 (2002-10-01), None
patent: WO-03/028758 (2003-04-01), None
Gorman C., The hope and the hype, May 1998, Time, v151, p. 37.
Zips D. et al., New anticancer agents:In vitro and In vivo evaluation, 2005, in vivo, v19, p. 1-9.
U.S. Appl. No. 10/528,360, filed Mar. 18, 2005, Sugiyama et al.
U.S. Appl. No. 11/322,245, filed Jan. 3, 2006, Sugiyama et al.
Tsuboi et al., Cancer Immunol Immunother., (Dec. 2002), vol. 51, No. 11-12, pp. 614 to 620.
Makita et al., Clin Cancer Res., (Aug. 2002), vol. 8, No. 8, pp. 2626 to 2631.
L. Meadows et al.,Immunity, vol. 6, 273-281, Mar. 1997.
Y. Kawakami et al.,The Journal of Immunology, 1998, 161: 6985-6992.
D. J. Kittlesen et al.,The Journal of Immunology, 1998, 160: 2099-2106.
K. M. Call et al.,Cell, vol. 60, 509-520, Feb. 9, 1990.
U.S. Appl. No. 09/744,815, filed Jan. 30, 2001, Sugiyama et al.
U.S. Appl. No. 10/517,600, filed Dec. 13, 2004, Sugiyama et al.
U.S. Appl. No. 10/527,692, filed Mar. 11, 2005, Sugiyama.
U.S. Appl. No. 11/196,452, filed Aug. 4, 2005, Sugiyama et al.
U.S. Appl. No. 10/541,821, filed Jul. 11, 2005, Sugiyama et al.
U.S. Appl. No. 10/562,486, filed Dec. 27, 2005, Sugiyama.
Gotoh Masashi
Kusunose Naoto
Nakatsuka Masashi
Samizo Fumio
Sugiyama Haruo
Chugai Seiyaku Kabushiki Kaisha
Dainippon Sumitomo Pharma Co. ,Ltd.
Gupta Anish
International Institute of Cancer Immunology, Inc.
Niebauer Ronald T
LandOfFree
WT1 substitution peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with WT1 substitution peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and WT1 substitution peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3928922